Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
about
Improving the risk assessment of lipophilic persistent environmental chemicals in breast milkCombining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataPKQuest_Java: free, interactive physiologically based pharmacokinetic software package and tutorial.A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.A framework incorporating the impact of exposure scenarios and application conditions on risk assessment of chemicals applied to skin.Development of a human Physiologically Based Pharmacokinetic (PBPK) Toolkit for environmental pollutants.Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in RatsCutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology ParadigmsPerformance Assessment and Translation of Physiologically Based Pharmacokinetic Models from acslX™ to Berkeley Madonna™, MATLAB®, and R language: Oxytetracycline and Gold Nanoparticles as Case Examples.MEGen: A Physiologically Based Pharmacokinetic Model Generator.Partition coefficients for nonane and its isomers in the rat.Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats.Challenges Associated with Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.Recognizing the importance of exposure-dose-response dynamics for ecotoxicity assessment: nitrofurazone-induced antioxidase activity and mRNA expression in model protozoan Euplotes vannus.
P2860
Q26849356-792FF15F-743C-4029-9D69-77FA412838FAQ30666721-197418BC-425C-45DC-9FB0-ADF8B0E2D588Q33490823-9A5D0EE9-9094-4989-9353-26F3D6FA528AQ33891588-95C85B41-887F-4184-B0DD-83ED2981306AQ34505158-783FF493-69D9-4F49-8880-F57C4BE1CBD6Q35600112-D48A5540-AC5D-48EE-8780-41599445DC69Q36039390-B1268C48-122F-42AE-8825-C8CF96D7B6B7Q36147843-9342BE77-FFBF-44BF-81A0-7019E9B8BBD1Q38731345-93AD5EC7-2131-43DB-9747-50F215881567Q39017720-1D01C038-07CF-4372-8E68-F154928EF51CQ42870666-4DE1C143-03CE-43D6-BD33-E5EDD8868B2BQ44095316-2D69D748-6CCB-4E0D-9761-F6C5D52D18A1Q49551649-5EF0369B-0625-49AC-A8D1-EA626E62A990Q50969067-C63FAF96-9741-4657-B126-2B90F1C95EC1
P2860
Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Approaches for applications of ...... tic models in risk assessment.
@en
Approaches for applications of ...... tic models in risk assessment.
@nl
type
label
Approaches for applications of ...... tic models in risk assessment.
@en
Approaches for applications of ...... tic models in risk assessment.
@nl
prefLabel
Approaches for applications of ...... tic models in risk assessment.
@en
Approaches for applications of ...... tic models in risk assessment.
@nl
P2093
P2860
P1476
Approaches for applications of ...... tic models in risk assessment.
@en
P2093
Babasaheb Sonawane
Chad M Thompson
Hugh A Barton
John C Lipscomb
Kannan Krishnan
Paul Schlosser
Robert S DeWoskin
Weihsueh A Chiu
P2860
P304
P356
10.1080/10937400701724337
P577
2008-08-01T00:00:00Z